Stilbenophane Analogues of
Deoxycombretastatin A-4
Carmen Mateo, Concepci o´ n P e´ rez-Melero,
Rafael Pel a´ ez,* and Manuel Medarde*
Laboratorio de Qu ı´ mica Org a´ nica y Farmac e´ utica,
Universidad de Salamanca, Facultad de Farmacia, Campus
“
Miguel de Unamuno”, E-37007, Salamanca, Spain
FIGURE 1. Structure of combretastatin A-1 (CA1), combre-
tastatin A-4 (CA4), its 3′-deoxyanalogue (DCA4), and designed
stilbenophane 4a.
pelaez@usal.es; medarde@usal.es
Received April 26, 2005
FIGURE 2. Retrosynthetic analysis of synthesized stil-
benophanes. Ring-closing metathesis (Y ) CH ) or McMurry
2
olefination (Y ) O) was the methodology selected for the
A new family of polyoxygenated stilbenophanes has been
synthesized as conformationally restricted analogues of
antimitotic combretastatins. By means of the McMurry
olefination process, compounds derived from diethyleneglycol
and 1,6-hexanediol were obtained, whereas Grubbs’ catalyst
failed in producing the ring-closing metathesis to this kind
of macrocyclic products.
macrocyclization process.
cellular transport agents.8 The combination of cyclo-
9
phanes and crown ethers is known as crownophanes.
During our research directed at the synthesis and
evaluation of new cytotoxic agents based on natural
10
products, we designed several macrocyclic derivatives
of the antimitotic agents combretastatin A-4 and related
compounds (Figure 1).11
Diversely substituted paracyclophane derivatives are
compounds of interest due to their structural features
These compounds are polyoxygenated stilbenophanes
macrocyclized through a polymethylene(polyether) chain
sharing in part the structure of crownophanes. The
presence of hexamethylene or 3-oxapentamethylene link-
ers restrict the conformational freedom of combreta-
statins, because they occupy the space between the two
rings. This fact prevents the adoption of conformations
in which the phenyl rings could be close to the coplanarity
with the double bond. The synthesis of these derivatives
and the study of the effect on their particular conforma-
tions and biological activities are very interesting in the
search for new bioactive compounds. We planned the
synthesis of title compounds as depicted in Figure 2. For
synthetic simplicity and versatility, we selected the
formation of the stilbenic double bond as the macrocy-
1
and properties. Among the paracyclophanes, the so-
2
called stilbenophanes have two aromatic systems linked
by an olefinic bridge. Polyether linkages between aro-
matic systems are found in interesting organic com-
pounds such as the crown ethers, their main use being
3
as complexing agents for cations (coronands and other
4
supramolecular hosts ). They have also been used as
5
6
catalysts, polymeric materials, and molecular machines
7
and switches. However, less frequent are those display-
ing biological activity as in the use of rotaxanes as
(1) (a) V o¨ gtle, F.; Neumann, P. Tetrahedron 1970, 26, 5847. (b)
Keehn, P. M., Rosenfeld, S. M., Eds. Cyclophanes; Academic Press:
New York, 1983; Vols. 1 and 2. (c) V o¨ gtle, F. Cyclophane Chemistry;
Wiley: Chichester, UK, 1993.
(
2) (a) Rajakumar, P.; Murali, V. Tetrahedron 2004, 60, 2351-2360.
(
b) Gierschner, J.; Mack, H. G.; Oelkrug, D.; Waldner, I.; Rau, H. J.
(8) Dvornikovs, V.; House, B. E.; Kaetzel, M.; Dedman, J. R.;
Smithrud, D. B. J. Am. Chem. Soc. 2003, 125, 8290-8301.
Phys. Chem. A 2004, 108, 257-263. (c) Ernst, L. Prog. Nucl. Magn.
Reson. Spectrosc. 2000, 37, 47-190. (d) Tanner, D.; Wennerstrom, O.
Tetrahedron Lett. 1981, 22, 2313-2316.
(9) (a) Furstner, A.; Seidel, G.; Kopiske, C.; Kruger, C.; Mynott, R.
Liebigs Ann. 1996, 655-662. (b) Hiratani, K.; Sakamoto, N.; Kameta,
N.; Karikomia, M.; Nagawa, Y. E. Chem. Commun. 2004, 1474-1475.
(c) Inokuma, S.; Sakai, S.; Nishimura, J. In Cyclophanes; 1994; Vol.
172, pp 87-118. (d) Inokuma, S.; Funaki, T.; Hara, D.; Nishimura, J.
Heterocycles 2004, 63, 333-346. (e) Lukyanenko, N. G.; Kirichenko,
T. I.; Lyapunov, A. Y.; Kulygina, C. Y.; Siminov, Y. A.; Fonari, M. S.;
Botoshansky, M. M. Tetrahedron Lett. 2004, 45, 2927-2930.
(10) (a) Lignans: Madrigal, B.; Puebla, P.; Pel a´ ez, R.; Caballero, E.;
Medarde, M. J. Org. Chem. 2003, 68, 854-864. (b) Indolocarbazole
alkaloids: Adeva, M.; Sahagun, H.; Caballero, E.; Pel a´ ez, R..; Medarde,
M.; Tom e´ , F. J. Org. Chem. 2000, 65, 3387-3394. (c) Combretast-
atins: P e´ rez-Melero, C.; Maya, A. B. S.; del Rey, B.; Pel a´ ez, R.;
Caballero, E.; Medarde, M. Bioorg. Med. Chem. Lett. 2004, 14, 3771-
3774. Maya, A. B. S.; P e´ rez-Melero, C.; Mateo, C.; Alonso, D.;
Fern a´ ndez, J. L.; Gajate, C.; Mollinedo, F.; Pel a´ ez, R.; Caballero, E.;
Medarde, M. J. Med. Chem. 2005, 48, 556-568.
(
3) Marquis, D.; Desvergne, J. P.; Bouas-Laurent, H. J. Org. Chem.
1
995, 60, 7984-7996.
4) Hellier, P. C.; Bradshaw, J. S.; Young, J. J.; Zhang, X. X.; Izatt,
R. M. J. Org. Chem. 1996, 61, 7270-7275.
5) (a) Sharghi, H.; Nasseri, M. A.; Niknam, K. J. Org. Chem. 2001,
6, 7287-7293. (b) Sharghi, H.; Massah, A. R.; Eshghi, H.; Niknam,
K. J. Org. Chem. 1998, 63, 1455-1461.
6) (a) Pearson, A. J.; Gelormini, A. M. J. Org. Chem. 1995, 60, 281-
84. (b) Komura, K.; Itsuno, S.; Ito, K. Chem. Commun. 1999, 35-36.
7) (a) Ashton, P. R.; Baldoni, V.; Balzani, V.; Credi, A.; Hoffmann,
(
(
6
(
2
(
H. D. A.; Mart ´ı nez-D ´ı az, M. V.; Raymo, F. M.; Stoddart, J. F.; Venturi,
M. Chem. Eur. J. 2001, 7, 3482-3493. (b) Badjic J. D.; Balzani, V.;
Credi, A.; Lowe, J. N.; Silvi, S.; Stoddart, J. F. Chem. Eur. J. 2004.
1
0, 1926-1935. (c) Ashton, P. R.; Balzani, V.; Becher, J.; Credi, A.;
Fyfe, M. C. T.; Mattersteig, G.; Menzer, S.; Nielsen, M. B.; Raymo, F.
M.; Stoddart, J. F.; Venturi, M.; Williams, D. J. J. Am. Chem. Soc.
1
(11) Lin, C. M.; Singh, S. B.; Chu, P. S.; Dempcy, R. O.; Schmidt, J.
M.; Pettit, G. R.; Hamel, E. Mol. Pharm. 1988, 34, 200-208.
999, 121, 3951-3957.
10.1021/jo0508393 CCC: $30.25 © 2005 American Chemical Society
6544
J. Org. Chem. 2005, 70, 6544-6547
Published on Web 07/14/2005